JNJ-90014496

JNJ-90014496 is a CAR-T cell therapy developed by Janssen Research & Development. Its targets are CD19 and CD20 (the sponsor names CD20 x CD19). The sponsor states: An autologous dual-targeting chimeric antigen receptor (CAR) T-cell therapy directed against both CD20 and CD19, enabling the engineered T cells to attack lymphoma cells expressing either or both antigens. ClinicalTrials.gov describes the intervention as: JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma and diffuse large B-cell lymphoma. The largest, NCT05421663, plans to enrol 166 participants (actual) with primary completion expected 2041-07-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.